• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Westlake Chemical Partners LP

    5/10/24 4:43:54 PM ET
    $WLKP
    Major Chemicals
    Industrials
    Get the next $WLKP alert in real time by email
    S-8 POS 1 d825302ds8pos.htm S-8 POS S-8 POS

    As filed with the Securities and Exchange Commission on May 10, 2024

    Registration No. 333-198233

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Post-Effective Amendment No. 1

    to

    Form S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    WESTLAKE CHEMICAL PARTNERS LP

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   32-0436529

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

    2801 Post Oak Boulevard, Suite 600

    Houston, Texas

      77056
    (Address of principal executive offices)   (Zip code)

     

     

    WESTLAKE CHEMICAL PARTNERS LP

    LONG-TERM INCENTIVE PLAN

    (As Amended and Restated Effective May 8, 2024)

    (Full title of the plan)

     

     

    L. Benjamin Ederington

    Executive Vice President, Performance and Essential Materials,

    General Counsel, Chief Administrative Officer and Director

    Westlake Chemical Partners GP LLC

    2801 Post Oak Boulevard, Suite 600

    Houston, Texas 77056

    (713) 585-2900

    (Name, Address and Telephone Number, Including Area Code, of Agent for Service)

     

     

    Copies to:

    Timothy S. Taylor

    Carina L. Antweil

    Baker Botts L.L.P.

    910 Louisiana Street

    Houston, Texas 77002

    (713) 229-1234

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☒
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    EXPLANATORY NOTE

    On August 19, 2014, Westlake Chemical Partners LP (the “Registrant” or the “Partnership”) filed a Registration Statement on Form S-8 (File No. 333-198233) (the “Registration Statement”) with the Securities and Exchange Commission (the “Commission”) relating to the registration of 1,270,000 common units representing limited partner interests (“Common Units”) issuable pursuant to awards granted under the Westlake Chemical Partners LP Long-Term Incentive Plan (the “Prior Plan”).

    This Post-Effective Amendment No. 1 to the Registration Statement (this “Post-Effective Amendment”) is being filed by the Registrant to reflect the amendment and restatement of the Westlake Chemical Partners LP Long-Term Incentive Plan as of May 8, 2024 (the “2024 Plan”), which extended the duration of the Prior Plan for ten years. The 2024 Plan was adopted by the board of directors of Westlake Chemical Partners GP LLC, a Delaware limited liability company and the general partner (the “General Partner”) of the Registrant, and approved by the Registrant’s unitholders at its special meeting of unitholders held on May 8, 2024 (the “Special Meeting”).

    Upon unitholder approval of the 2024 Plan, the Partnership’s authority to grant new awards under the Prior Plan terminated and 1,198,853 Common Units that had been available for new award grants under the Prior Plan immediately prior to the Special Meeting became available for grants under the 2024 Plan. As provided in the 2024 Plan, any Common Units subject to awards outstanding under the Prior Plan that are forfeited, cancelled, exercised, settled in cash or otherwise terminate or expire without the actual delivery of Common Units pursuant to such award, or any Common Units under an award that are held back to cover the exercise price or tax withholding, are available to satisfy future awards under the 2024 Plan. As of the date of the Special Meeting, a total of 18,564 Common Units were subject to awards then outstanding under the Prior Plan.

    The filing fee for the registration of the offer of Common Units under the 2024 Plan was paid in full upon the filing of the Registration Statement. Pursuant to the Commission’s Compliance and Disclosure Interpretation 126.43, no filing fee is due upon the filing of this Post-Effective Amendment.

    Except to the extent specified herein, the Registration Statement as previously filed is not amended or otherwise affected by this Post-Effective Amendment thereto.

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    Note: The document(s) containing the information concerning the 2024 Plan required by Item 1 of Form S-8 and the statement of availability of registrant information and any other information required by Item 2 of Form S-8 will be sent or given to participants as specified by Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”). In accordance with Rule 428 and the requirements of Part I of Form S-8, such documents are not being filed with the Commission either as part of the Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act. The Registrant shall maintain a file of such documents in accordance with the provisions of Rule 428. Upon request, the Registrant shall furnish to the Commission or its staff a copy or copies of all of the documents included in such file.


    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    ITEM 3. Incorporation of Documents by Reference.

    The following documents have been filed with the Commission by the Partnership (File No. 001-36567) pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and are hereby incorporated in the Registration Statement by reference:

     

      (1)

    The Partnership’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023;

     

      (2)

    The Partnership’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024;

     

      (3)

    The Partnership’s Current Report on Form 8-K filed on May 8, 2024; and

     

      (4)

    The description of our Common Units contained in the Registration Statement on Form 8-A filed on July 24, 2014, as updated by the description of our Common Units filed as Exhibit 4.1 to our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, and as we may further update that description from time to time.

    All documents filed with the Commission by the Partnership pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (excluding information deemed to be furnished and not filed with the Commission) subsequent to the date hereof and prior to the filing of another post-effective amendment to the Registration Statement which indicates that all securities offered hereby have been sold, or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part hereof from the date of filing of such documents.

    Any statement contained herein or incorporated by reference herein shall be deemed to be modified or superseded for purposes of the Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as modified or superseded, to constitute a part of the Registration Statement.

    ITEM 4. Description of Securities.

    Not applicable.

    ITEM 5. Interests of Named Expert and Counsel.

    Not applicable.

    ITEM 6. Indemnification of Directors and Officers.

    Subject to any terms, conditions, or restrictions set forth in the Registrant’s First Amended and Restated Agreement of Limited Partnership, as amended (the “Partnership Agreement”), Section 17-108 of the Delaware Revised Uniform Limited Partnership Act empowers a Delaware limited partnership to indemnify and hold harmless any partner or other persons from and against any and all claims and demands whatsoever.

    Section 7.7(a) of the Partnership Agreement provides that the Registrant will indemnify and hold harmless the following persons, in most circumstances, to the fullest extent permitted by law, from and against all losses, claims, damages, liabilities (joint or several) expenses (including legal fees and expenses), judgments, fines, penalties, interest, settlements or other amounts arising from any and all threatened, pending or completed claims, demands, actions, suits or proceedings, whether civil, criminal, administrative or investigative, and whether formal or informal and including appeals, in which such person may be involved, or is threatened to be involved, as a party or otherwise, by reason of its status as an indemnitee and acting (or refraining to act) in such capacity:

     

      •  

    the General Partner, as the general partner of the Registrant;


      •  

    any departing general partner of the Registrant (a “Departing GP”);

     

      •  

    any person who is or was an affiliate of the General Partner or any Departing GP;

     

      •  

    any person who is or was a manager, managing member, general partner, director, officer, fiduciary or trustee of the Registrant, its subsidiaries, the General Partner, any Departing GP or any of their respective affiliates;

     

      •  

    any person who is or was serving as an officer, director, manager, managing member, general partner, employee, agent, fiduciary or trustee of another person owing a fiduciary duty to the Registrant or its subsidiaries;

     

      •  

    any person who controls the General Partner or any Departing GP; or

     

      •  

    any person designated by the General Partner.

    Any indemnification under these provisions will be made only out of the assets of the Registrant. Unless the General Partner agrees otherwise, the General Partner will not be personally liable for, or have any obligation to contribute or loan any monies or property to the Registrant to enable it to effectuate, such indemnification.

    Section 7.7(d) of the Partnership Agreement states that the Registrant may purchase and maintain (or reimburse the General Partner or its affiliates for the cost of) insurance, on behalf of the General Partner, its affiliates and such other persons as the General Partner determines, covering liabilities that may be asserted against, or expense that may be incurred by, such persons in connection with the Registrant’s activities or such person’s activities on behalf of the Registrant, regardless of whether the Registrant would have the power to indemnify such person against such liabilities under the Partnership Agreement.

    Subject to any terms, conditions or restrictions set forth in the First Amended and Restated Limited Liability Company Agreement of Westlake Chemical Partners GP LLC (the “LLC Agreement”), Section 18-108 of the Delaware Limited Liability Company Act provides that a Delaware limited liability company may indemnify and hold harmless any member or manager or other person from and against any and all claims and demands whatsoever.

    Section 5.10 of the LLC Agreement provides that the General Partner will indemnify and hold harmless the following persons, in most circumstances, to the fullest extent permitted by law, from and against any and all losses, claims, damages, liabilities, joint or several, expenses (including legal fees and expenses), judgments, fines, penalties, interest, settlements or other amounts arising from any and all threatened, pending or completed claims, demands, actions, suits or proceedings, whether civil, criminal, administrative or investigative, and whether formal or informal and including appeals, in which any such person may be involved, or is threatened to be involved, as a party or otherwise, by reason of its status as an indemnitee and acting (or refraining to act) in such capacity:

     

      •  

    Westlake International Services Corporation, the sole member of the General Partner;

     

      •  

    any person who is or was an affiliate of the General Partner;

     

      •  

    any person who is or was a member, partner, director, officer, fiduciary or trustee of the General Partner, the Registrant or its subsidiaries;

     

      •  

    any person who is or was serving at the request of the sole member of the General Partner as a member, partner, director, officer, fiduciary or trustee of another person; and

     

      •  

    any person the General Partner designates as an indemnitee for purposes of the LLC Agreement.


    The General Partner may purchase and maintain (or reimburse its affiliates for the cost of) insurance, on behalf of the General Partner, its affiliates, any indemnitee described in the previous five bullets and such other persons as the General Partner determines, covering liabilities that may be asserted against, or expense that may be incurred by, such persons in connection with the General Partner’s activities or such person’s activities on behalf of the General Partner, regardless of whether the General Partner would have the power to indemnify such person against such liability under the LLC Agreement.

    The General Partner may enter into indemnity agreements with each of its current directors and officers to give such persons additional contractual assurances regarding the scope of the indemnification set forth in the LLC Agreement and to provide additional procedural protections.

    The 2024 Plan provides that the committee that administers the 2024 Plan (the “Committee”) and all members thereof are entitled to, in good faith, rely or act upon any report or other information furnished to them by any officer or employee of the Registrant, the General Partner, any of their affiliates, the Registrant’s or General Partner’s legal counsel, independent auditors, consultants or any other agents assisting in the administration of this Plan. Members of the Committee and any officer or employee of the General Partner, the Registrant, or any of their affiliates acting at the direction or on behalf of the Committee shall not be personally liable for any action or determination taken or made in good faith with respect to the 2024 Plan, and shall, to the fullest extent permitted by law, be indemnified and held harmless by the General Partner with respect to any such action or determination.

    ITEM 7. Exemption from Registration Claimed.

    Not applicable.


    ITEM 8. Exhibits.

    The following documents are filed as part of the Registration Statement or incorporated by reference herein:

     

     4.1    Certificate of Limited Partnership of Westlake Chemical Partners LP (incorporated by reference to Exhibit 3.1 to Westlake Chemical Partners LP’s Registration Statement on Form S-1 (File No. 333-195551), filed on April 29, 2014).
     4.2    First Amended and Restated Agreement of Limited Partnership of Westlake Chemical Partners LP (incorporated by reference to Exhibit 3.1 to Westlake Chemical Partners LP’s Current Report on Form 8-K (File No. 001-36567) filed on August 8, 2014).
     4.3    Amendment No.  1 to the First Amended and Restated Agreement of Limited Partnership of Westlake Chemical Partners LP dated as of November 16, 2017 (incorporated by Reference to Exhibit 3.1 to Westlake Chemical Partners LP’s Current Report on Form 8-K, filed on November 16, 2017, File No. 01-36567).
     4.4    Amendment No.  2 to the First Amended and Restated Agreement of Limited Partnership of Westlake Chemical Partners LP (incorporated by reference to Exhibit 3.1 to Westlake Chemical Partners LP’s Current Report on Form 8-K filed on July 30, 2018 (File No. 01-36567)).
     4.5    Westlake Chemical Partners LP Long-Term Incentive Plan (Adopted July  15, 2014) (incorporated by reference to Exhibit 10.8 to Westlake Chemical Partners LP’s Current Report on Form 8-K (File No.  001-36567) filed on August 8, 2014).
     4.6    Westlake Chemical Partners LP Long-Term Incentive Plan (As Amended and Restated Effective May  8, 2024) (incorporated by reference to Appendix A of Westlake Chemical Partners LP’s Definitive Proxy Statement on Schedule 14A (File No. 001-36567) filed on March 18, 2024).
     5.1    Opinion of Vinson  & Elkins L.L.P. as to the legality of the securities being registered (incorporated by reference to Westlake Chemical Partners LP’s Registration Statement on Form S-8 (File No. 333-198233) filed on August 19, 2014).
     5.2*    Opinion of Baker Botts L.L.P. as to the legality of the securities being registered.
    23.1*    Consent of PricewaterhouseCoopers LLP.
    23.2    Consent of Vinson & Elkins L.L.P. (included in Exhibit 5.1).
    23.3*    Consent of Baker Botts L.L.P. (included in Exhibit 5.2).
    24.1*    Power of Attorney (included on the signature page hereto).

     

    *

    Filed herewith.

    ITEM 9. Undertakings.

     

      (a)

    The undersigned registrant hereby undertakes:

     

      (1)

    To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

      (i)

    To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

      (ii)

    To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) of the Securities Act if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and


      (iii)

    To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

    provided, however, that the undertakings set forth in paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this registration statement.

     

      (2)

    That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

      (3)

    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

      (b)

    The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

      (c)

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Houston, State of Texas, on May 10, 2024.

     

    WESTLAKE CHEMICAL PARTNERS LP
    (Registrant)
    By:   Westlake Chemical Partners GP LLC,
      its general partner
    By:  

    /s/ Albert Chao

      Albert Chao
      President, Chief Executive Officer and Director

    POWER OF ATTORNEY

    Each person whose signature appears below appoints Albert Chao, M. Steven Bender and L. Benjamin Ederington, and each of them severally, as his or her true and lawful attorney or attorneys-in-fact and agent or agents, with full power to act with or without the others and with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to the Registration Statement, and to file the same, with all exhibits thereto and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority, to do and perform in the name and on behalf of each undersigned, in any and all capacities, each and every act and thing necessary or desirable to be done, in all intents and purposes and as fully as he or she might or could do in person, hereby ratifying, approving and confirming all that said attorneys-in-fact and agents, and each of them, or the substitute or substitutes of any or all of them, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment to the Registration Statement has been signed by the following persons in the capacities indicated on May 10, 2024.

     

    Signature

      

    Title

    /s/ Albert Chao

    Albert Chao

      

    President, Chief Executive Officer and Director

    (Principal Executive Officer)

    /s/ M. Steven Bender

    M. Steven Bender

      

    Executive Vice President, Chief Financial Officer and Director

    (Principal Financial Officer)

    /s/ Jeff Holy

    Jeff Holy

      

    Vice President and Chief Accounting Officer

    (Principal Accounting Officer)

    /s/ L. Benjamin Ederington

    L. Benjamin Ederington

       Executive Vice President, Performance and Essential Materials, General Counsel, Chief Administrative Officer and Director

    /s/ James Chao

    James Chao

       Chairman of the Board of Directors

    /s/ G. Stephen Finley

    G. Stephen Finley

       Director


    Signature

      

    Title

    /s/ Lisa Friel

    Lisa Friel

       Director

    /s/ Randy Woelfel

    Randy Woelfel

       Director
    Get the next $WLKP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WLKP

    DatePrice TargetRatingAnalyst
    3/2/2022$30.00 → $31.00Buy
    Deutsche Bank
    7/16/2021$27.00Buy → Underperform
    BofA Securities
    More analyst ratings

    $WLKP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Gilson Jean-Marc bought $2,025 worth of Common Units (95 units at $21.25), increasing direct ownership by 0.81% to 11,803 units (SEC Form 4)

    4 - Westlake Chemical Partners LP (0001604665) (Issuer)

    8/29/25 3:36:25 PM ET
    $WLKP
    Major Chemicals
    Industrials

    President and CEO Gilson Jean-Marc bought $163,637 worth of Common Units (7,461 units at $21.93), increasing direct ownership by 176% to 11,708 units (SEC Form 4)

    4 - Westlake Chemical Partners LP (0001604665) (Issuer)

    8/28/25 8:33:56 AM ET
    $WLKP
    Major Chemicals
    Industrials

    Amendment: President and CEO Gilson Jean-Marc bought $7,344 worth of Common Units (320 units at $22.95), increasing direct ownership by 10% to 3,427 units (SEC Form 4)

    4/A - Westlake Chemical Partners LP (0001604665) (Issuer)

    8/28/25 8:33:42 AM ET
    $WLKP
    Major Chemicals
    Industrials

    $WLKP
    SEC Filings

    View All

    SEC Form 10-Q filed by Westlake Chemical Partners LP

    10-Q - Westlake Chemical Partners LP (0001604665) (Filer)

    10/31/25 3:02:46 PM ET
    $WLKP
    Major Chemicals
    Industrials

    Westlake Chemical Partners LP filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Westlake Chemical Partners LP (0001604665) (Filer)

    10/30/25 7:33:19 AM ET
    $WLKP
    Major Chemicals
    Industrials

    SEC Form 144 filed by Westlake Chemical Partners LP

    144 - Westlake Chemical Partners LP (0001604665) (Subject)

    8/15/25 4:31:25 PM ET
    $WLKP
    Major Chemicals
    Industrials

    $WLKP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Westlake Chemical Partners LP Announces Third Quarter 2025 Results

    Renewed Ethylene Sales Agreement through 2027 at existing terms Declared quarterly distribution of $0.4714 per unit; 45th consecutive quarterly distribution Westlake Chemical Partners LP (NYSE:WLKP) (the "Partnership") today reported net income attributable to the Partnership in the third quarter of 2025 of $14.7 million, or $0.42 per limited partner unit, which was below third quarter 2024 net income of $18.1 million. Cash flows from operating activities in the third quarter of 2025 were $105.2 million, a decrease of $20.9 million compared to third quarter 2024 cash flows from operating activities of $126.1 million. For the three months ended September 30, 2025, MLP distributable ca

    10/30/25 6:30:00 AM ET
    $WLKP
    Major Chemicals
    Industrials

    Westlake Chemical Partners Announces Renewal of Ethylene Sales Agreement

    Westlake Chemical Partners LP (NYSE:WLKP) (the "Partnership") announced that Westlake Chemical OpCo LP ("OpCo") and Westlake Corporation ("Westlake") agreed to renew the Ethylene Sales Agreement between the parties through December 31, 2027 in accordance with its terms, which provides for an initial term through December 31, 2026 and automatic 12-month renewal periods until terminated at the end of the initial term or any renewal term on not less than 12-months' notice. The renewal of the Ethylene Sales Agreement will facilitate continued offtake on attractive terms for 95% of the ethylene produced by OpCo. The renewed agreement maintains the same pricing formula and sales volume protecti

    10/30/25 6:00:00 AM ET
    $WLKP
    Major Chemicals
    Industrials

    Westlake Chemical Partners LP Announces Third Quarter 2025 Distribution

    $0.4714 per unit distribution declared payable on November 26, 2025 The Board of Directors of Westlake Chemical Partners GP LLC, the general partner of Westlake Chemical Partners LP (the "Partnership") (NYSE:WLKP), has declared a distribution of $0.4714 per unit. This is the 45th quarterly distribution announced by the Partnership since its initial public offering. The distribution will be payable on November 26, 2025, to unit holders of record on November 10, 2025. This release is intended to be a qualified notice under Treasury Regulation Section 1.1446-4(b). Brokers and nominees should treat one hundred percent (100.0%) of the Partnership's distributions to non-U.S. investors as be

    10/28/25 4:16:00 PM ET
    $WLKP
    Major Chemicals
    Industrials

    $WLKP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Gilson Jean-Marc bought $2,025 worth of Common Units (95 units at $21.25), increasing direct ownership by 0.81% to 11,803 units (SEC Form 4)

    4 - Westlake Chemical Partners LP (0001604665) (Issuer)

    8/29/25 3:36:25 PM ET
    $WLKP
    Major Chemicals
    Industrials

    President and CEO Gilson Jean-Marc bought $163,637 worth of Common Units (7,461 units at $21.93), increasing direct ownership by 176% to 11,708 units (SEC Form 4)

    4 - Westlake Chemical Partners LP (0001604665) (Issuer)

    8/28/25 8:33:56 AM ET
    $WLKP
    Major Chemicals
    Industrials

    Amendment: President and CEO Gilson Jean-Marc bought $7,344 worth of Common Units (320 units at $22.95), increasing direct ownership by 10% to 3,427 units (SEC Form 4)

    4/A - Westlake Chemical Partners LP (0001604665) (Issuer)

    8/28/25 8:33:42 AM ET
    $WLKP
    Major Chemicals
    Industrials

    $WLKP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Deutsche Bank reiterated coverage on Westlake Chemical with a new price target

    Deutsche Bank reiterated coverage of Westlake Chemical with a rating of Buy and set a new price target of $31.00 from $30.00 previously

    3/2/22 9:14:17 AM ET
    $WLKP
    Major Chemicals
    Industrials

    Westlake Chemical Partners downgraded by BofA Securities with a new price target

    BofA Securities downgraded Westlake Chemical Partners from Buy to Underperform and set a new price target of $27.00

    7/16/21 8:38:08 AM ET
    $WLKP
    Major Chemicals
    Industrials

    Westlake Chemical downgraded by UBS with a new price target

    UBS downgraded Westlake Chemical from Buy to Neutral and set a new price target of $25.00 from $23.00 previously

    3/18/21 7:11:14 AM ET
    $WLKP
    Major Chemicals
    Industrials

    $WLKP
    Financials

    Live finance-specific insights

    View All

    Westlake Chemical Partners LP Announces Third Quarter 2025 Results

    Renewed Ethylene Sales Agreement through 2027 at existing terms Declared quarterly distribution of $0.4714 per unit; 45th consecutive quarterly distribution Westlake Chemical Partners LP (NYSE:WLKP) (the "Partnership") today reported net income attributable to the Partnership in the third quarter of 2025 of $14.7 million, or $0.42 per limited partner unit, which was below third quarter 2024 net income of $18.1 million. Cash flows from operating activities in the third quarter of 2025 were $105.2 million, a decrease of $20.9 million compared to third quarter 2024 cash flows from operating activities of $126.1 million. For the three months ended September 30, 2025, MLP distributable ca

    10/30/25 6:30:00 AM ET
    $WLKP
    Major Chemicals
    Industrials

    Westlake Chemical Partners Announce Third Quarter 2025 Earnings Conference Call

    Westlake Chemical Partners (NYSE:WLKP) will release its third quarter 2025 earnings prior to the market opening on Thursday, October 30, 2025. The company will host a conference call at 1:00 p.m. Eastern Time (12:00 p.m. Central Time) on the same day to discuss the earnings release. To access the conference by phone, it is necessary to pre-register at https://register-conf.media-server.com/register/BI18a27e98796e4538920bcc251d12d94a. Once registered, you will receive a phone number and unique PIN number. When you dial in, you will input the PIN number to be placed into the call. The conference call and replay will be available via webcast at https://edge.media-server.com/mmc/p/zo2bvgiu

    10/16/25 9:00:00 AM ET
    $WLKP
    Major Chemicals
    Industrials

    Westlake Chemical Partners LP Announces Second Quarter 2025 Results

    Declared quarterly distribution of $0.4714 per unit; 44th consecutive quarterly distribution Westlake Chemical Partners LP (NYSE:WLKP) (the "Partnership") today reported net income attributable to the Partnership in the second quarter of 2025 of $14.6 million, or $0.41 per limited partner unit, which was in line with second quarter 2024 net income of $14.4 million. Cash flows from operating activities in the second quarter of 2025 were $9.1 million, a decrease of $112.8 million compared to second quarter 2024 cash flows from operating activities of $121.9 million. For the three months ended June 30, 2025, MLP distributable cash flow was $15.0 million, a decrease of $2.1 million compared

    8/5/25 6:30:00 AM ET
    $WLKP
    Major Chemicals
    Industrials

    $WLKP
    Leadership Updates

    Live Leadership Updates

    View All

    Westlake Chemical Partners Appoints Lisa Friel to Board of Directors

    Westlake Chemical Partners (NYSE:WLKP) today announced that Ms. Lisa A. Friel has been appointed to the board of directors of its general partner, Westlake Chemical Partners GP LLC. She will replace Ms. Angela A. Minas, who previously informed the company that she would resign from the board effective upon the appointment of her successor. Ms. Friel was the Managing Partner of Ernst & Young LLP's San Antonio, Texas office from July 2012 until her retirement in September 2020. Ms. Friel began her career with Ernst & Young LLP in 1988. She is currently the Chair of the Board of Directors for the United Way of San Antonio. Ms. Friel holds a bachelor's of science degree in Accounting and Busi

    4/27/23 4:15:00 PM ET
    $WLKP
    Major Chemicals
    Industrials

    Woodside Energy Group Ltd Announces Changes to Woodside Board

    Retirement of Dr Sarah Ryan and Dr Christopher Haynes from the Woodside BoardPERTH, AUSTRALIA / ACCESSWIRE / March 8, 2023 / The Board of Woodside announces the retirement of Dr Sarah Ryan and Dr Christopher Haynes as Directors of Woodside. Dr Ryan and Dr Haynes will be standing down from their respective offices with effect from the conclusion of Woodside's 2023 Annual General Meeting, scheduled to be held on 28 April 2023 (2023 AGM).Dr Haynes has served on Woodside's Board since 2011 and is a member of the Audit & Risk Committee, the Sustainability Committee and the Nominations & Governance Committee.Dr Ryan joined the Woodside Board in December 2012 and serves on the Audit & Risk Committe

    3/8/23 2:20:00 AM ET
    $CEQP
    $WDS
    $WLKP
    Oil & Gas Production
    Utilities
    Energy
    Major Chemicals

    Crestwood Appoints Two New Independent Directors Solidifying its Leading MLP Corporate Governance Model

    Crestwood Equity Partners LP (NYSE:CEQP) ("Crestwood") announced today that Angela A. Minas and Clay C. Williams have been appointed to serve on the Board of Directors of its general partner effective January 1, 2022. "I am pleased to welcome Angela and Clay to the Crestwood Board of Directors. Both of these highly regarded individuals bring a wealth of U.S. and global industry experience and perspective to our boardroom that will greatly benefit Crestwood as we navigate the dynamic energy industry and take advantage of opportunities to continue building a leading midstream infrastructure company," said Robert G. Phillips, Chairman, President and Chief Executive Officer of Crestwood's gene

    11/11/21 1:00:00 PM ET
    $BHE
    $CEQP
    $CINR
    Electrical Products
    Technology
    Oil & Gas Production
    Utilities

    $WLKP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Westlake Chemical Partners LP (Amendment)

    SC 13D/A - Westlake Chemical Partners LP (0001604665) (Subject)

    2/14/24 4:19:23 PM ET
    $WLKP
    Major Chemicals
    Industrials

    SEC Form SC 13G/A filed by Westlake Chemical Partners LP (Amendment)

    SC 13G/A - Westlake Chemical Partners LP (0001604665) (Subject)

    2/14/24 2:02:09 PM ET
    $WLKP
    Major Chemicals
    Industrials

    SEC Form SC 13G/A filed by Westlake Chemical Partners LP (Amendment)

    SC 13G/A - Westlake Chemical Partners LP (0001604665) (Subject)

    2/12/24 4:43:59 PM ET
    $WLKP
    Major Chemicals
    Industrials